Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery

Table 3 Semi-quantitative immunopositivity (score 0 to 3) and number of positive samples in the diagnostic colonic tissue samples of pediatric ulcerative colitis patients and non inflammatory bowel disease patients

	Surgery (n = 24)	Conservative treatment controls (n = 27)	Non-IBD controls (n = 20)	P valueSurgery vs conservative treatment controls	P valueSurgery vs non-IBD controls
Number of positive samples n (%)
Tryp-1
Epithelium	13 (57)	19 (76)	15 (79)	0.22	0.19
Stroma; inflammatory cells	11 (48)	8 (32)	5 (26)	0.38	0.21
Tryp-2
Epithelium	21 (95)	21 (81)	18 (95)	0.20	0.22
TATI
Epithelium	18 (78)	24 (92)	15 (75)	0.23	1.00
MMP-9
Epithelium	4 (18)	2 (8)	0 (0)	0.40	0.17
Stroma; inflammatory cells	11 (50)	12 (48)	1 (5)	1.00	0.0061
Median immunopositivity
Tryp-1
Epithelium	1.0	2.0	2.0	0.032	0.042
Stroma; inflammatory cells	0.0	0.0	0.0	0.16	0.10
Tryp-2
Epithelium	1.0	1.0	1.0	0.56	0.38
TATI
Epithelium	1.0	1.0	1.0	0.81	0.97
MMP-9
Epithelium	0.0	0.0	0.0	0.33	0.17
Stroma; inflammatory cells	0.5	0.0	0.0	0.89	0.0033

¹Both UC patient groups had significantly more positively stained inflammatory cells in their colonic epithelium when compared to the non-IBD controls;

²The patients who had undergone surgery had significantly lower immunopositivity when compared to the conservatively treated and non-IBD controls;

³Both UC patient groups had significantly higher immunopositivity when compared to the non-IBD controls. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; TATI: Trypsin inhibitor; Tryp-2: Trypsinogen-2; MMP-9: Matrix metalloproteinase-9.